Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Barclays Sticks to Their Sell Rating for Zimmer Biomet Holdings (ZBH)

Tipranks - Tipranks - Fri Feb 13, 6:10AM CST

In a report released today, Matt Miksic from Barclays maintained a Sell rating on Zimmer Biomet Holdings, with a price target of $100.00.

Valentine's Day Sale - 70% Off

Miksic covers the Healthcare sector, focusing on stocks such as Johnson & Johnson, Abbott Laboratories, and Cooper Co. According to TipRanks, Miksic has an average return of 4.6% and a 56.24% success rate on recommended stocks.

In addition to Barclays, Zimmer Biomet Holdings also received a Sell from UBS’s Danielle Antalffy in a report issued yesterday. However, on the same day, TipRanks – PerPlexity upgraded Zimmer Biomet Holdings (NYSE: ZBH) to a Buy.

See today’s best-performing stocks on TipRanks >>

Based on Zimmer Biomet Holdings’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $2.24 billion and a net profit of $139.5 million. In comparison, last year the company earned a revenue of $2.02 billion and had a net profit of $239.5 million

Read More on ZBH:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).